Click and hear Paul G. Richardson present the data for the combination therapy with elotuzumab in combination pomalidomide and dexamethasone for relapsed/refractory multiple myeloma. Elotuzumab, an immunostimulatory monoclonal antibody targeting SLAMF7, enables selective killing of MM cells through multiple mechanisms of action and synergizes with the immunomodulatory drug pomalidomide. This study demonstrated sustained and clinically relevant PFS and OS benefits for elotuzumab plus pomalidomide and dexamethasone vs pomalidomide in combination with dexamethasone, with no new safety signals. These data support the long-term favorable efficacy–safety profile of elotuzumab plus pomalidomide and dexamethasone and suggest this regimen could be considered as a standard of care for patients with relapsed/refractory multiple myeloma after failure of lenalidomide and a proteasome inhibitor.
The Nordic Myeloma Study Group (NMSG) initiated the CARFI trial, an open randomized phase II study, to investigate the efficacy and safety of carfilzomib as part of induction and conditioning in salvage ASCT and to evaluate the role of carfilzomib/dexamethasone maintenance after salvage ASCT. In this MEDtalk Henrik Gregersen report that maintenance therapy with carfilzomib and dexamethasone maintenance prolongs median time to progression with approximately 6 months following salvage ASCT in multiple myeloma.